EVOGENIX IPO CLOSES OVERSUBSCRIBED

Antibody therapeutic company EvoGenix has closed its $9 million initial public offer early following strong support from institutional and retail investors. The Sydney-based company closed oversubscribed, issuing 36 million shares at 25 a share. It is expected to list on the Australian Stock Exchange early next month. Evogenix managing director Merilyn Sleigh said the float had attracted strong interest with more than a dozen institutions investing in the offer.

Australian Financial Review (http://afr.com/articles/2005/07/28/1122143942368.html)